-
JBCRG-M03
A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
- Status
-
No Longer Recruiting
- Objectives
-
To evaluate the usefulness of eribulin in combination with trastuzumab and pertuzumab as first line or second line therapy for patients with advanced or recurrent HER2-positive breast cancer.
- Subjects
-
- Endpoints
-
Progression free survival(PFS) Response rate(RR)、Safety、Overall survival(OS)、Efficacy after prior use of pertuzumab, Compliance of eribulin, Efficacy of later therapy
- Trial Period
-
- Lead Principal Investigator
-
Toshinari Yamashita (Kanagawa Cancer Center, Department of Breast and Endocrine Surgery)
- Target Sample Size
-
48
- Regimen
-
eribulin, trastuzumab, and pertuzumab
- Source of Funding
-
JBCRG (Japan Breast Cancer Research Group)
- Conference Presentation
-
Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03)
- Articles and Publications
-
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: A multicenter, single arm, phase II study (JBCRG-M03 study)
- UMIN-ID
-
UMIN000012232
- jRCT
-
- Memo
-
- COI Disclosure
-
